Law360, New York (October 24, 2007, 12:00 AM ET) -- A high court in London on Wednesday clarified that inventors on a patent need to prove that they contributed to the invented concept, clearing the way for Yeda Research & Development Co. Ltd. to be named as the inventor of a patent covering the cancer drug Erbitux.
The House of Lords handed down a unanimous decision in the dispute over who invented the subject matter of a key patent covering the use of Israeli pharmaceutical company ImClone Systems Inc.’s Erbitux.
It found that “a person who...
U.K. Court Lets Yeda Continue Case Over Erbitux
To view the full article, take a free trial now.
